uploads/2017/12/Chart-008-2-1.jpg

How AstraZeneca’s Other Products Portfolio Performed in 3Q17

By

Updated

Other products segment

AstraZeneca’s (AZN) other products portfolio includes various drugs for infections, neuroscience drugs, and gastrointestinal drugs. The other products segment reported revenues of $991 million during 3Q17, a 17% decline in operating revenues driven by lower sales of Losec, FluMist, Nexium, Seroquel XR, and a few other products, partially offset by increased sales of Movantik and Synagis.

The above chart compares revenues for key other products over the last few quarters.

Losec

Losec reported revenues of $66 million during 3Q17, an 8% decline in operating revenues as compared to 3Q16. The decline was due to lower sales of Losec in US markets, European markets, and established rest of the world markets. However, the decline was partially offset by growth in the sales from emerging markets during 3Q17.

Movantik

Movantik reported revenues of $30 million during 3Q17, a 20% increase in operating revenues as compared to 3Q16. The growth was driven by increased sales from the US markets and European markets during 3Q17.

Nexium

Nexium reported revenues of $469 million during 3Q17, a 7% decline in operating revenues as compared to 3Q16. The decline was due to lower sales across all the markets worldwide. The US markets reported Nexium sales of $103 million, the established rest of the world markets reported Nexium sales of $138 million, the European markets reported Nexium sales of $56 million, and the emerging markets reported Nexium sales of $172 million during 3Q17.

Synagis

Synagis reported 47% growth in revenues at constant exchange rates to $153 million during 3Q17. The growth was driven by strong sales in both US and European markets. The European markets reported 44% growth in revenues at constant exchange rates to $138 million, while the US sales rose 88% to $15 million during 3Q17.

The iShares Global Healthcare ETF (IXJ) holds 1.8% of its total investments in AstraZeneca (AZN), 1.5% in Biogen (BIIB), 1.8% in GlaxoSmithKline (GSK), and 1.8% in Celgene (CELG).

More From Market Realist